

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.



May 7, 2025

To whom it may concern

Company name: JMDC Inc.

Representative: Ryo Noguchi,

President and CEO

(TSE Prime Market, Stock Code: 4483)

Contact: Yuzuru Kubota,

Executive Officer and CFO

(E-mail: [ir@jmdc.co.jp](mailto:ir@jmdc.co.jp))

**(Progress of disclosure matters)**

**Notice Concerning Recording of Gain on Sale Due to Transfer of Subsidiary**

In the “Notice of Changes in Subsidiaries (Transfer of Shares) and in Reportable Segments” disclosed on February 20, 2025, JMDC Inc. (the “Company”) announced the transfer of shares in our consolidated subsidiaries. At that time, we announced that the impact on the full-year consolidated results for FY2024 and the gain on the transfer of subsidiary were being examined. Today, we have determined the impact, and the details are as follows.

**I. Summary of the shares transfer**

In order to ensure the sustainable growth and enhance the corporate value of NOAH MEDICAL SYSTEM CORPORATION. (the “NOAH MEDICAL”), the Company resolved at the meeting of its Board of Directors held on February 20, 2025 to transfer all shares of NOAH MEDICAL, and completed the transfer on February 21, 2025.

**II. Impact on the Company's business results**

As a result of this shares transfer, the Company recorded a gain on sale of business of JPY 2,075 million in the consolidated financial results for FY2024. In addition, the Company recorded a gain on sale of shares in affiliated companies of JPY 2,304 million in the non-consolidated financial results. The impact of this shares transfer is reflected in the “Summary of Financial Statements for the Fiscal Year Ended March 31, 2025 [IFRS] (Consolidated)” announced today.